NEW YORK, Oct. 30 - Prolinx has "drastically reduced" its headcount and frozen some marketing activities as it tries to reel in cash burn and wrap up development of its Acapella technology, the company said yesterday.
Registering provides access to this and other free content.
Already have an account?Login Now.
In PNAS this week: mutations linked to nasopharyngeal carcinoma, salivary proteins common among oral squamous cell carcinoma patients, and more.
At Wired, a science journalist discusses her decision not to undergo BRCA testing.
The Japan Times says regulations are needed to oversee human genome-editing research.
In PLOS this week: molecular surveillance of S. Typhi, genome-wide association study of attention in children, and more.